Investors
Overview

Investors Overview

Company Profile

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

Press Releases
Read more
Recent/Upcoming Events
Nov 08, 2026 at 11:45 AM MST
(AASLD) The Liver Meeting® 2026 - Oral Presentation

Session: Clinical Trial Pipeline for MASH 2026

Abstract Title: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis

Speaker: Dr. Naim Alkhouri

Nov 07, 2026 at 1:00 PM MST
(AASLD) The Liver Meeting® 2026 - Poster Presentation

Session: MASLD/MASH Therapeutics

Abstract Title: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial

Speaker: Dr. Mazen Noureddin

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Email: ir@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe